Chardan Capital Has Positive Outlook of LXEO FY2025 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Research analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for shares of Lexeo Therapeutics in a note issued to investors on Tuesday, April 8th. Chardan Capital analyst G. Livshits now expects that the company will earn ($3.06) per share for the year, up from their previous forecast of ($3.10). Chardan Capital has a "Buy" rating and a $22.00 price target on the stock. The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.14) per share.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.09.

A number of other research analysts also recently issued reports on LXEO. Royal Bank of Canada cut their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 25th. HC Wainwright reiterated a "buy" rating and issued a $23.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, April 8th. Finally, Leerink Partners lowered their target price on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a research note on Monday, March 24th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Lexeo Therapeutics presently has an average rating of "Buy" and an average price target of $22.20.

Lexeo Therapeutics Price Performance

Shares of LXEO traded down $0.31 during mid-day trading on Friday, hitting $2.24. 328,800 shares of the company traded hands, compared to its average volume of 645,540. The business has a 50-day moving average of $3.20 and a 200 day moving average of $5.88. The stock has a market capitalization of $74.36 million, a price-to-earnings ratio of -0.71 and a beta of 1.52. Lexeo Therapeutics has a one year low of $1.45 and a one year high of $19.50. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Lexeo Therapeutics

Several large investors have recently made changes to their positions in LXEO. Allostery Investments LP acquired a new position in shares of Lexeo Therapeutics during the 4th quarter worth about $33,000. BNP Paribas Financial Markets boosted its stake in shares of Lexeo Therapeutics by 184.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock worth $50,000 after acquiring an additional 3,591 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Lexeo Therapeutics during the fourth quarter worth approximately $46,000. JPMorgan Chase & Co. increased its stake in Lexeo Therapeutics by 135.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company's stock worth $93,000 after acquiring an additional 5,915 shares during the period. Finally, Price T Rowe Associates Inc. MD acquired a new position in Lexeo Therapeutics in the fourth quarter valued at about $69,000. Institutional investors and hedge funds own 60.67% of the company's stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.